ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
ClearPoint Neuro Inc

ClearPoint Neuro Inc (CLPT)

12.50
0.50
( 4.17% )
Updated: 13:47:22

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
12.50
Bid
12.49
Ask
12.50
Volume
88,394
11.9378 Day's Range 12.572
5.105 52 Week Range 14.125
Market Cap
Previous Close
12.00
Open
12.04
Last Trade
1
@
12.4974
Last Trade Time
13:47:31
Financial Volume
$ 1,094,835
VWAP
12.3859
Average Volume (3m)
204,788
Shares Outstanding
27,584,699
Dividend Yield
-
PE Ratio
-6.41
Earnings Per Share (EPS)
-0.8
Revenue
23.96M
Net Profit
-22.09M

About ClearPoint Neuro Inc

MRI Interventions Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ... MRI Interventions Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace system, which is under development, to be used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint Neuro Intervention System and The ClearTrace Cardiac Intervention System. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
ClearPoint Neuro Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CLPT. The last closing price for ClearPoint Neuro was $12. Over the last year, ClearPoint Neuro shares have traded in a share price range of $ 5.105 to $ 14.125.

ClearPoint Neuro currently has 27,584,699 shares outstanding. The market capitalization of ClearPoint Neuro is $331.02 million. ClearPoint Neuro has a price to earnings ratio (PE ratio) of -6.41.

CLPT Latest News

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.544.5150501672211.9612.6311.8312151012.18337525CS
4-0.86-6.437125748513.3613.8610.1524085711.73631912CS
120.413.3912324234912.0914.12510.1520478812.10460071CS
266.81119.6836555365.6914.1255.112186849.66007038CS
526.49107.9866888526.0114.1255.1051796448.43430146CS
1560.43.3057851239712.116.964.051573918.97952261CS
2606.9123.2142857145.631.292.860118089312.80080548CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYCNCyclerion Therapeutics Inc
$ 7.2136
(348.05%)
115.72M
SMXSMX Security Matters Public Company
$ 0.512549
(163.12%)
457.13M
CNEYCN Energy Group Inc
$ 0.593026
(87.90%)
155.23M
SRMSRM Entertainment Inc
$ 1.1208
(77.88%)
133.89M
HTOOFusion Fuel Green PLC
$ 0.559
(75.79%)
267.09M
RLMDRelmada Therapeutics Inc
$ 0.643
(-76.79%)
14.06M
MIGIMawson Infrastructure Group Inc
$ 0.8422
(-55.91%)
10.9M
MONDMondee Holdings Inc
$ 0.1998
(-32.29%)
2.58M
ORISOriental Rise Holdings Ltd
$ 8.48
(-29.04%)
507.23k
FGLFounder Group Limited
$ 2.95
(-27.70%)
9.79M
SMXSMX Security Matters Public Company
$ 0.512549
(163.12%)
457.13M
SVMHSRIVARU Holding Ltd
$ 0.0267
(21.36%)
438.3M
HTOOFusion Fuel Green PLC
$ 0.559
(75.79%)
267.09M
CNEYCN Energy Group Inc
$ 0.593026
(87.90%)
155.23M
SRMSRM Entertainment Inc
$ 1.1208
(77.88%)
133.89M

CLPT Discussion

View Posts
Monksdream Monksdream 6 months ago
CLPT under $10
👍️0
Mortimerduke Mortimerduke 11 months ago
Putting their funding to good use!
👍️0
MasterBlastr MasterBlastr 3 years ago
50% haircut last 6 months. Glad I didn't buy when you were hyping this. Looks like you are gone too.
👍️0
VMLG17 VMLG17 3 years ago
Plenty of talk of her on the NWBO board. I'm long on NWBO.
👍️0
oderwacher oderwacher 3 years ago
Doesn't anybody ever talk about Dr. Linda Liau?
👍️0
ronpopeil ronpopeil 4 years ago
I bought in. Very exciting company
👍️0
DayTraderOG DayTraderOG 4 years ago
Oh wow great dip time to scoop some shares on sale
👍️0
DayTraderOG DayTraderOG 4 years ago
Nice news clear point neuro doing big things saving our lives go $CLPT https://www.globenewswire.com/news-release/2021/01/26/2164680/0/en/ClearPoint-Neuro-Inc-Announces-Expansion-of-Pre-Clinical-and-Translational-Development-Team-to-Support-Gene-and-Stem-Cell-Therapy-Partners.html
👍️0
DayTraderOG DayTraderOG 4 years ago
This stock has been great runner daily
👍️0
DayTraderOG DayTraderOG 4 years ago
Everyone missing out on this great stock of the year
👍️0
DayTraderOG DayTraderOG 4 years ago
Good after noon CLPT
👍️0
DayTraderOG DayTraderOG 4 years ago
Going be great in am
👍️0
DayTraderOG DayTraderOG 4 years ago
Yall missed this gem
👍️0
DayTraderOG DayTraderOG 4 years ago
Wow from 7 to 23 if u missed me calling out CLPT where were u
👍️0
DayTraderOG DayTraderOG 4 years ago
Good morning clear point looks like shell be going 30 today by end of week
👍️0
DayTraderOG DayTraderOG 4 years ago
All new highs here anyone missing this ?? losing a lot of free cash
👍️0
MWM MWM 4 years ago
$CLPT very Nice! I have too many plays!!! Very Nice!

👍️0
DayTraderOG DayTraderOG 4 years ago
$CLPT
Keep going up
👍️0
DayTraderOG DayTraderOG 4 years ago
Yall missing out on all this love
👍️0
DayTraderOG DayTraderOG 4 years ago
I like this gem keeps going up like stair case this will be at $50 easy
👍️0
MWM MWM 4 years ago
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms

https://www.globenewswire.com/news-release/2020/12/29/2151415/0/en/ClearPoint-Neuro-Inc-Announces-Funding-of-Additional-7-5M-of-Existing-Convertible-Note-on-Improved-Terms.html
👍️0
DayTraderOG DayTraderOG 4 years ago
Ive been in since July its been a great ride for me
👍️0
MWM MWM 4 years ago
Nice Find
👍️0
MWM MWM 4 years ago
CLPT one to watch...

Outstanding Shares 16,869,528 11/10/2020

Brain surgery

The Restore-1 trial DSMB did not advise Neurocrine's team to pause or halt the trial back in November, Roberts said. However, it did recommend that the company discontinue its use of the neurosurgical procedure used in the trial at the time, she said. That was presumably a reference to the brain surgery procedure by which NBIb-1817 and another Voyager asset, VY-HTT-01, are designed to be delivered to targeted areas and cells in the brain.

In a previous phase I trial, conducted by the University of California, San Francisco, three patients experienced hemorrhages caused by the surgical procedure for administering VY-AADC, Voyager reported in its most recent quarterly report, on Nov. 9.

In response, in Restore-1, investigators began using Clearpoint Neuro Inc.'s Clearpoint System "to provide accurate placement of the cannula in the putamen and allow for real-time, intra-operative MRI to assist the physician in visualizing the delivery of VY-AADC (NBIb-1817) to the putamen and to avoid specific blood vessels during the duration of the surgical procedure, with the goal of reducing the risk of hemorrhages," Voyager said.

In the same quarterly filing, Voyager said that it might begin using V-TAG, a real-time, intra-operative, MRI-compatible device that it developed with Clearpoint for the procedures.

Even with those changes, the Restore-1 study had been on pause since earlier in the year due to what Roberts called a "major amendment to the study over the course of the summer," one that appears to have included a major streamlining of the trial's primary and secondary outcome measures. Furthermore, screening for the study had been paused as well, particularly in light of the need for trial participants to travel, sometimes across state lines for study-relating brain scans.

Neurocrine's efforts to resolve those issues weren't clear on Wednesday. But Cowen analyst Phil Nadeau remained cautiously optimistic. "The risk to NBIb-1817's further development, as well as the duration of the delay, can't be estimated without understanding the specific issues that the DSMB has identified," he said.

https://www.bioworld.com/articles/501751-fda-puts-parkinsons-trial-on-hold-amid-imaging-abnormalities



👍️0
DayTraderOG DayTraderOG 4 years ago
Wow im glad I know about this gem steadily going up lets have another great say $CLPT
👍️0
DayTraderOG DayTraderOG 4 years ago
This stock will be at 50 dollars one day soon don't get left out this gem
👍️0
DayTraderOG DayTraderOG 4 years ago
Don't sleep on this ticker is the way of future surgery
👍️0
DayTraderOG DayTraderOG 4 years ago
Watching the dips today
👍️0

Your Recent History

Delayed Upgrade Clock